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The aim of this study was to investigate the inﬂuence of tumor necrosis factor-α (TNF-α) in temporomandibular joint (TMJ)
synovial ﬂuid and blood on the treatment eﬀect on TMJ pain by intra-articular injection of glucocorticoid in patients with chronic
inﬂammatory TMJ disorders. High pretreatment level of TNF-α in the synovial ﬂuid was associated with a decrease of TNF-α
and elimination of pain upon maximal mouth opening. Elimination of this TMJ pain was accordingly associated with decrease in
synovial ﬂuid level of TNF-α. There was also a signiﬁcant decrease of C-reactive protein and TMJ resting pain after treatment. In
conclusion, this study indicates that presence of TNF-α in the synovial ﬂuid predicts a treatment eﬀect of intra-articular injection
of glucocorticoid on TMJ movement pain in patients with chronic TMJ inﬂammatory disorders.
Copyright © 2006 Lars Fredriksson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Glucocorticoids administered systemically or locally sup-
press inﬂammation and pain in patients with systemic in-
ﬂammatory disorders such as rheumatoid arthritis (RA;[1]).
Glucocorticoids act on cytoplasmic glucocorticoid recep-
tors that upon activation inhibit the expression of genes for
proinﬂammatory cytokines such as tumor necrosis factor-α
(TNF-α), while increasing the expression of genes encoding
anti-inﬂammatory proteins such as the soluble receptor II of
TNF-α, which has been shown to reduce arthritis [2]. Glu-
cocorticoids have an inhibitory eﬀect on inﬂammatory me-
diator release from many cell types involved in inﬂamma-
tion such as macrophages, T-lymphocytes, mast cells, den-
dritic cells, and neutrophilic leukocytes. Glucocorticoids also
reduce prostaglandin production by inhibition of the phos-
pholipase A2 enzyme [1]. TNF-α is elevated in plasma and
synovial ﬂuid of patients with chronic inﬂammatory disor-
ders like RA [3–6]. Elevated plasma levels of TNF-α are con-
sidered pathological and are part of the systemic inﬂamma-
tory response [7]. TNF-α has direct modulatory eﬀects on
painandtissuedegradationbutalsohasindirecteﬀectsbyin-
ducing production of other proinﬂammatory cytokines like
interleukin-1 (IL-1), IL-6, and IL-8 [8–11]. Nordahl et al
[5] showed that patients with chronic inﬂammatory connec-
tive tissue disease and associated temporomandibular joint
(TMJ) pain have elevated TNF-α levels in the synovial ﬂuid
compared to those without pain. Since glucocorticoids sup-
presspainandinﬂammation,systemicandperipheralTNF-α
mightbeexpectedtoinﬂuencethetreatmenteﬀectsoflocally
administered glucocorticoids.
Our hypothesis is that a diﬀerence in the peripheral ex-
pression of inﬂammation in the TMJ, as reﬂected by the
proinﬂammatory mediator TNF-α, is important for the lo-
cal treatment response. This may explain a diﬀerence in the
treatment response to, for example, glucocorticoid and that
the treatment response may diﬀer regarding symptoms and
signs.
The aim of this study was to investigate the inﬂuence of
TNF-α in TMJ synovial ﬂuid and blood on the treatment ef-
fect on TMJ pain by intra-articular injection of glucocorti-
coid in patients with chronic inﬂammatory disorders of the
TMJ.
MATERIALS AND METHODS
Patients
Twenty one female patients with chronic inﬂammatory
TMJ disease participated (Table 1). Inclusion criteria were
the presence of seropositive or seronegative RA (n = 5,
resp), ankylosing spondylitis (n = 3), psoriatic arthropathy2 Mediators of Inﬂammation
Table 1: Demographic data for 21 female patients with chronic
inﬂammatory temporomandibular joint (TMJ) disorders subjected
to intra-articular glucocorticoid injections. The patients were asked
about pain in nine joint regions besides the TMJ (neck, shoulders,
elbows, hands, upper back, lower back, hips, knees, and feet) and
the number of painful joint regions was recorded (score = 0–9),
IQR = 75th–25th percentile, n = number of patients.
Median IQR n
Age (years) 48 22 21
Duration of general
joint involvement (years) 10 19 21
Duration of local
TMJ involvement (years) 3 9 20
Number of painful
joint regions (0–9) 7 3 21
(n = 3), chronic unspeciﬁc polyarthritis (n = 2), Marfan’s
syndrome (n = 2), or osteoarthritis (n = 1) with unilateral
or bilateral presence of TMJ inﬂammatory disorder accord-
ing to the diagnostic classiﬁcation by the American Academy
of Orofacial Pain [12] with the modiﬁcation that pain with
mandibular function or point tenderness on TMJ palpation
was mandatory. An additional criterion was that at least one
of the proinﬂammatory mediators TNF-α,I L - 1 β,o rs e r o -
tonin or a pathological level (90th percentile 348pg/mL) of
the anti-inﬂammatory mediator interleukin-1 receptor an-
tagonist (IL-1Ra) was present in the synovial ﬂuid directly
before or after treatment. The purpose of the use of several
inﬂammatory mediators was to validate the clinical diagno-
sis of local arthritis for inclusion in this study. No diﬀer-
ence in the composition of mediators in the synovial ﬂuid
was observed between the clinical diagnostic subgroups. The
exclusion criterion was intra-articular glucocorticoid treat-
ment of the TMJ within 3 months before treatment. All pa-
tients were referred to the clinic from rheumatologists or
general medical practitioners who determined the primary
diagnosis before enrollment in this study except for the pa-
tient with osteoarthritis. Eight patients regularly used non-
steroidal anti-inﬂammatory drugs (Celecoxib, Diclofenac,
Ibuprofen, Ketoprofen, Nabumetone, or Naproxen), ﬁve pa-
tients used oral glucocorticoid (Prednisolone), six patients
used disease-modifying antirheumatic drugs (Sulfazalasine,
Methotrexate), whereas eight patients had no current anti-
inﬂammatory treatment. The study was approved by the Lo-
cal Ethical Committee at Karolinska University Hospital in
Huddinge, Sweden (142/02 and 176/91).
Clinicalexamination
The current TMJ pain intensity at rest was assessed with a
100mm visual analogue scale on paper with endpoints de-
noted by “no pain” (0mm) and “worst pain ever experi-
enced” (100mm). The presence or absence of TMJ pain on
maximum mouth opening was also recorded. Change from
presence to absence of movement pain thus means a total
elimination of pain. Absence or presence of tenderness and
palpebral pain reﬂex to digital palpation of the lateral and
posterior (through the acustic meatus) aspects of the TMJ
were assessed with the mandible in rest position.
Thepressure-painthresholdoverthepalpablelateralpole
of the TMJ condyle with the patient’s mandible in a rest
position was determined with a single measurement by a
handheld electronic pressure algometer (Somedic Produc-
tion AB, Sollentuna, Sweden), consisting of a pressure trans-
ducer probe connected to a pistol grip with a display unit.
The tip of the pressure transducer has a ﬂat, circular rubber
tip with an area of 1cm2. A linearly increasing pressure rate
(50kPa/s2)[ 13–15] was applied until the subject responded
to the ﬁrst pain sensation by pressing a button on a device
connected to the probe that froze the current pressure-pain
threshold level on the display. The pressure-pain threshold
was deﬁned as the minimum pressure needed to evoke a
painful sensation recognizable by the subject.
Synovialﬂuidsamplingfrom
thetemporomandibularjoint
TMJ anesthesia was achieved by blocking the auriculotem-
poral nerve with 2mL 2% lidocain (Xylocain, Astra-Zeneca,
S¨ odert¨ alje,Sweden).TheTMJwaspuncturedwithastandard
disposable needle (diameter = 0.65mm) inserted into the
posterior part of the upper joint compartment. TMJsynovial
ﬂuid samples were obtained by washing the joint cavity with
salineusingapushandpulltechnique[16].Brieﬂy,thewash-
ing solution, consisting of 78% saline (NaCl 9mg/mL, Phar-
macia Upjohn, Uppsala, Sweden) and 22% hydroxocobal-
amin (Behepan 1mg/mL; Pharmacia Upjohn, Uppsala, Swe-
den), was slowly injected into the posterior part of the up-
per joint cavity approximately 1mL at a time and then aspi-
rated. The total volume of the washing solution injected was
4mL. The hydroxocobalamin was included in order to deter-
mine the volume of synovial ﬂuid recovered in the aspirate
by comparing the spectrophotometric absorbance of the as-
pirate with that of the washing solution. The synovial ﬂuid
level was then calculated. Only samples that fulﬁlled previ-
ously established sample quality criteria were included in the
statistical analysis [16].
Bloodsampling
Venous blood was collected in a sodium citrate tube
(0.105mol/L) to determine the erythrocyte sedimentation
rate and in an EDTA tube that was immediately cooled
and centrifuged (1500g for 10 minutes at +4
ÆC) and then
frozen (
￿70
ÆC), and later examined for TNF-α in plasma.
In addition, venous blood was collected without additives
for analysis of thrombocyte particle count and CRP level in
serum. Time from freezing to analysis varied between 1 and
6 months for the samples.
Treatmentandexaminationschedule
The glucocorticoid methylprednisolone (40mg/mL) with li-
docaine (10mg/mL) added (Depo-Medrol cum lidocaine;
Pﬁzer AB, T¨ aby, Sweden) was injected in a volume of 0.7mL
into the upper joint compartment of the TMJ. In the patientsLars Fredriksson et al 3
withbilateralTMJpain,whoweresubjectedtobilateraltreat-
ment, data from the most painful TMJ was used in the statis-
ticalanalysis.ThemostpainfulTMJwasthatwiththehighest
pain intensity at rest before treatment.
The patients were examined before and after treatment.
The median (interquartile range, IQR) interval between the
ﬁrst and second examinations was 40 (40) days. At the ﬁrst
visit, the glucocorticoid was injected into the TMJ after clin-
ical examination and synovial ﬂuid sampling. At the second
visit, clinical examination and synovial ﬂuid sampling were
performed.
Analysisoftumornecrosisfactor-α
Plasma TNF-α was determined with an immunoenzymo-
metric assay (Medgenix TNF-α EASIA kit, BioSource Europe
Sa, Zoning Industriel B-6220, Fleurus, Belgium) with a de-
tection limit of 3pg/mL. The intra-assay coeﬃcient of vari-
ation for this assay is 3.7%–5.2% and the inter-assay vari-
ation is 8%–9.9% according to the manufacturer. The me-
dian (75th/90th percentile) level of TNF-α in blood plasma
from healthy individuals examined in our laboratory is 10
(12/18)pg/mL, while TNF-α is undetectable in TMJ synovial
ﬂuid in healthy individuals. The concentration of synovial
ﬂuid levels of TNF-α was analyzed as the same assay used for
plasma,butitwasmodiﬁedtocompensateforhydroxocobal-
amin interactions with the assay by using a standard curve
with hydroxocobalamin. The small hydroxocobalamin inter-
action was completely compensated for by this procedure.
Statisticalanalyses
Nonparametric descriptive and analytical statistics were ap-
plied since some of the investigated variables were not
normally distributed or measured on interval scales. The
Kolmogorov-SmirnovtestwasusedtotestifthevariableTMJ
pressure-pain threshold was normally distributed. The cen-
tral tendency and the variation of the variables are presented
as median and IQR (75th–25th percentile). The signiﬁcances
ofthediﬀerencesbetweenthevariablesbeforeandaftertreat-
ment were calculated by the Wilcoxon test. The signiﬁcances
of the diﬀerencesbetween the patient groups with a followup
interval shorter than 40 days and with a longer followup in-
terval regarding the synovial ﬂuid level of TNF-α were tested
with Mann-Whitney U test. Spearman’s ranked correlation
test was used to calculate the signiﬁcance of the correlations
betweenthevariables.Aprobabilitylevelbelow0.05wascon-
sidered as signiﬁcant.
RESULTS
Table 2 shows the clinical, synovial ﬂuid and blood variables
before and after treatment.
Tumornecrosisfactor-α
TNF-α was detectable in the synovial ﬂuid from seven pa-
tients before treatment and seven patients after treatment,
that is, 33% of the patients had detectable level at each oc-
casion but only one patient had detectable levels at both oc-
casions (Figure 1). Seven patients showed decreased, six in-
creased, and eight showed unchanged levels after treatment.
All patients with detectable pretreatment synovial ﬂuid level
of TNF-α showed a reduction of the mediator from a median
of 65 to a median of 0 (P = .018).
All plasma samples showed detectable pretreatment level
of TNF-α. Seven of the 12 patients with plasma samples
showed decreased TNF-α levels after treatment and ﬁve
showed increased levels. There was thus no consistent or sig-
niﬁcant change in plasma level of TNF-α after treatment.
There was no signiﬁcant diﬀerence regarding the change
of synovial ﬂuid TNF-α levels after treatment between the
patients with a followup interval shorter than the median in-
terval (40 days) compared to a longer followup interval.
Changesafterglucocorticoidtreatmentin
relationtopretreatmentTNF-αlevels
The pretreatment synovial ﬂuid level of TNF-α was nega-
tively correlated to the change in synovial ﬂuid TNF-α level
and TMJ pain upon maximum mouth opening, that is, a
high pretreatment synovial ﬂuid TNF-α level was associated
with a reduction of TNF-α in TMJ synovial ﬂuid and elimi-
nation of TMJ movement pain (rs =
￿0.86, n = 21, P<. 001
and rs =
￿0.51, n = 21, P = .017, resp; Figure 2)a f t e rt r e a t -
ment.
Relationbetweenchangesafter
glucocorticoidtreatment
The change in synovial ﬂuid TNF-α level after treatment was
positively correlated to the corresponding change in TMJ
pain upon maximum mouth opening (rs = 0.50, n = 21,
P = .020; Figure 3), that is, a decrease of TNF-α was associ-
ated with an elimination of TMJ pain.
The change in synovial ﬂuid TNF-α showed a tendency
to a positive correlation to the change in serum C-reactive
protein during the study period (rs = 0.47, n = 16, P =
.068), that is, an increased C-reactive protein level tended to
be associated with an increased synovial ﬂuid level of TNF-α.
C-reactive protein increased from already abnormal levels in
fourpatientsandfromnormallevelinone,whileitdecreased
in none.
Pretreatmentrelations
The synovial ﬂuid level of TNF-α was not signiﬁcantly corre-
lated to its plasma level (rs =
￿0.28, n = 14, P = .325).
The synovial ﬂuid TNF-α level was positively correlated
to TMJ pain intensity at rest (rs = 0.59, n = 20, P = .006;
Figure 4).
Thetendernesstodigitalpalpationoftheposterioraspect
of the TMJ was negatively correlated to the level of thrombo-
cyte particle concentration (rs =
￿0.56, n = 16, P = .024),
which in turn was positively correlated to erythrocyte sedi-
mentation rate (rs = 0.60, n = 17, P = .012) and C-reactive
protein level (rs = 0.56, n = 17, P = .018).4 Mediators of Inﬂammation
Table 2: General and temporomandibular joint (TMJ) variables before and after intra-articular administration of glucocorticoid (median
interval 40 days) in 21 female patients with chronic inﬂammatory TMJ disorders. The TMJ data refer to the most painful joint if bilateral
injections were performed.
Pretreatment Followup
Median IQR n % > 0% a b nMedian IQR n % > 0% a b n P
General disease activity
General joint pain intensity score 53 32 18 100 NA 31 38 14 93 NA NS
Erythrocyte sedimentation rate mm/ﬁrst h 91 6 1 9 N A5 12 18 16 NA 13 NS
C-reactive protein mg/L 01 1 1 8 2 82 8 0 12 17 29 29 0.043
C-reactive protein > 10mg/L mg/L 15 9 5 NA 100 26 22 5 NA 100 NA
Thrombocyte particle
concentration 109/L 307 102 17 NA 6 277 71 9 NA 11 NS
TMJ pain
Intensity at rest score 50 44 20 100 NA 28 66 18 80 NA 0.021
Present upon maximum
mouth opening 0o r1 — — 21 86 NA — — 21 67 NA NS
Tenderness to digital palpation
Lateral 0 or 1 — — 21 86 NA — — 21 43 NA 0.008
Posterior 0 or 1 — — 20 55 NA — — 21 29 NA 0.043
Sum 0–2 2 1 20 95 NA 1 0 21 52 NA 0.002
Pain reﬂex to digital palpation
Lateral 0 or 1 — — 21 29 NA — — 21 14 NA NS
Posterior 0 or 1 — — 20 15 NA — — 21 10 NA NS
Sum 0–2 0 1 20 30 NA 0 0 21 19 NA NS
Pressure-painthreshold
Temporomandibular joint kPa 123 58 21 NA NA 123 66 21 NA NA NS
Tumornecrosis factor-α
Synovial ﬂuid pg/mL 03 7 2 1 3 33 3 03 6 2 1 3 33 3 N S
Plasma pg/mL 14 13 14 100 57 12 12 14 100 43 NS
Pain intensity was assessed with a 100mm visual analogue scale (VAS), tenderness or palpebral pain reﬂex to digital palpation of the lateral
and posterior aspects of the TMJ on each side was recorded as one unit if the patient reported tenderness or if pain reﬂex was observed
and the pressure-pain threshold was assessed over the palpable lateral pole of the TMJ condyle. IQR = 75th–25th percentile, n = number of
patients, % > 0 = percentage of observations exceeding 0, % abn = percentage of observations exceeding normal levels, median and IQR are
not given for the 0/1 variables, NA = not applicable and NS = not signiﬁcant.
Presence of a palpebral pain reﬂex, but not tenderness,
on digital palpation of both lateral and posterior aspects of
the TMJ was negatively correlated to the TMJ pressure-pain
threshold (rs =
￿0.55, n = 21, P = .010 and rs =
￿0.51,
n = 20, P = .021, resp; Table 3).
DISCUSSION
This study indicates that local TNF-α-related mechanisms
inﬂuence the treatment eﬀect of glucocorticoids on TMJ
movement pain and that presence of TNF-α in synovial
ﬂuid predicts a positive treatment response in patients with
chronic inﬂammatory TMJ disorders. TMJ movement pain
is the clinical variable with the strongest relation to an in-
ﬂammatory condition of the TMJ as determined by presence
of inﬂammatory mediators in the synovial ﬂuid [5, 17]a n d
therefore the most valid clinical sign of TMJ arthritis.
High synovial ﬂuid TNF-α l e v e lb e f o r et r e a t m e n tw a sa s -
sociated with elimination of TMJ pain on maximum mouth
opening after treatment. A decrease of synovial ﬂuid TNF-α
levelaftertreatmentwasaccordinglyassociatedwithelimina-
tionofTMJpainonmaximummouthopening.Indeed,high
synovialﬂuidlevelofTNF-αhaspreviouslybeenshowntobe
associated with pain on maximum mouth opening [5]. Syn-
ovial ﬂuid TNF-α
  therefore seems to be predictive for glu-
cocorticoid treatment outcome of this particular TMJ pain
entity, which most probably is due to inhibition of intra-
articular pain mechanisms provoked by joint movement and
modulated by TNF-α. At the same time, patients with de-
tectable, that is, pathological, synovial ﬂuid TNF-α levels had
higher TMJ pain intensity in the TMJ at rest than those with
undetectable levels, which indicates that synovial TNF-α is
involved in modulation of resting pain as well. The plasma
level of TNF-α was not associated with TMJ pain in thisLars Fredriksson et al 5
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Figure 1: Individual changes in temporomandibular joint (TMJ)
synovial ﬂuid levels of tumor necrosis factor-α (TNF-α)b e f o r ea n d
after (median interval: 40 days) intra-articular glucocorticoid treat-
ment in 21 female patients with chronic inﬂammatory TMJ disor-
der. Eight patients had undetectable synovial ﬂuid levels of TNF-α
at both occasions. The patients with detectable pretreatment syn-
ovial ﬂuid level of TNF-α showed a reduction of the mediator from
a median of 65 to a median of 0.
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Figure 2: Box-plot (10th, 25th, 50th, 75th, and 90th percentiles)
showing the relation between pretreatment TMJ synovial ﬂuid level
of tumor necrosis factor-α (TNF-α) and the change in temporo-
mandibular joint (TMJ) pain upon maximum mouth opening after
intra-articular glucocorticoid treatment in 21 female patients with
chronic inﬂammatory disorders of the TMJ (rs = 0.51, n = 21,
P = .017). Four patients had an elimination and 17 had no change
of TMJ pain upon maximum mouth opening. In the 7 patients with
detectable pretreatment levels, 3 experienced an elimination and 4
no change in TMJ pain upon maximum mouth opening.
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Figure 3: Box-plot (10th, 25th, 50th, 75th, and 90th percentiles)
showing the relation between change in presence of temporo-
mandibular joint (TMJ) pain upon maximum mouth opening and
change in synovial ﬂuid level of tumor necrosis factor-α (TNF-α)
after intra-articular glucocorticoid treatment in 21 female patients
with chronic TMJ inﬂammatory disorders (rs = 0.50, n = 21,
P = .020). Four patients had an elimination and 17 had no change
of TMJ pain upon maximum mouth opening. In the 7 patients with
detectable pretreatment levels, 3 experienced an elimination and 4
no change in TMJ pain upon maximum mouth opening.
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Figure 4: Box-plot (10th, 25th, 50th, 75th, and 90th percentiles)
showing the pretreatment relation between temporomandibular
joint (TMJ) synovial ﬂuid level of tumor necrosis factor-α (TNF-α)
and TMJ resting pain intensity in 20 female patients with chronic
inﬂammatory TMJ disorders (rs = 0.59, n = 20, P = .006). Four-
teen patients had undetectable synovial ﬂuid TNF-α levels, whereas
seven had detectable levels.6 Mediators of Inﬂammation
Table 3: Pressure-pain threshold in relation to tenderness and
palpebral pain reﬂex to palpation before and 40 days after intra-
articularadministrationofglucocorticoidin21femalepatientswith
chronic inﬂammatory temporomandibular joint (TMJ) disorders.
Median(IQR)inkPa andnumberofobservations.Absenceorpres-
ence of tenderness and palpebral pain reﬂex to digital palpation
of the lateral and posterior (through the acoustic meatus) aspects
of the TMJ were assessed with the mandible in rest position (all
patients with a pain reﬂex had tenderness to palpation) and the
pressure-pain threshold was recorded over the palpable lateral pole
of the TMJ condyle, NA = not applicable and IQR = 75th–25th
percentile.
Tenderness to palpation
Palpebral pain
reﬂex to palpation
Lateral Posterior
No Yes No Yes
Before treatment
No 147 (73) 142 (70) 123 (49) 147 (84)
31 298
Yes NA 90 (53) NA 82 (68)
060 3
After treatment
No 120 (75) 129 (103) 123 (85) 74 (47)
1 261 5 4
Yes NA 98 (56) NA 76 (-)
030 2
study, whichindicatesaprimarily local,ratherthansystemic,
inﬂuence of TNF-α on the reduction of TMJ pain by gluco-
corticoid treatment and supports the previous ﬁnding that
TNF-α mediates pain in the synovial tissues of the TMJ [5].
TMJ resting pain and tenderness to digital palpation de-
creased after intra-articular glucocorticoid treatment, which
is in accordance with several previous studies [18–20]. In
this study, the tenderness to digital palpation of the posterior
aspect of the TMJ was negatively correlated to the level of
thrombocyte particle concentration which in turn was asso-
ciated with the inﬂammatory markers, erythrocyte sedimen-
tation rate, and C-reactive protein. This suggests that pos-
terior tenderness is not directly related to systemic inﬂam-
matory activity. Instead, local pain mechanisms are probably
more important, which would favour a response of this pain
entity to intra-articular glucocorticoid administration.
One explanation for the observed absence of treatment
eﬀect on pain on maximum mouth opening may be the large
proportion of patients with undetectable levels of synovial
ﬂuid TNF-α before treatment since detectable pretreatment
levels of synovial ﬂuid TNF-α were found to predict reduc-
tion of pain on maximum mouth opening.
There were no treatment eﬀects observed on presence
of palpebral pain reﬂex to digital TMJ palpation or TMJ
pressure-painthreshold.Thesevariableswereaccordinglyre-
lated to each other but not to the presence of tenderness to
palpation. The ﬁndings presented indicate that diﬀerent pain
mechanisms modulate tenderness to digital palpation on the
one hand and pain reﬂex to digital palpation and pressure-
painthresholdovertheTMJontheother.Consequently,glu-
cocorticoid actually seems to have diﬀerent eﬀects on diﬀer-
ent pain entities, which in part may be due to diﬀerent ori-
gins of these pain entities. TMJ pain on maximum mouth
opening is probably related to intra-articular pain mecha-
nisms [17], whereas TMJ pressure-pain threshold as well as
palpebral pain reﬂex probably are related to pain mecha-
nisms in the lateral periarticular tissues. It therefore seems
that there is a diﬀerence in mechanisms between pain re-
ﬂex and tenderness to palpation of the joint, which is diﬃ-
cult to explain but may include activation of diﬀerent sub-
sets of nociceptors. There are reasons to consider pain on
maximummouthopeningasintra-articularallodynia,which
corroborates earlier ﬁndings [17]. It has previously been hy-
pothesized that pressure-pain threshold and resting pain of
the TMJ are modulated by diﬀerent pain mechanisms [20],
which is supported by the results of this study since there was
no relation between these variables which responded diﬀer-
ently to local administration of glucocorticoid. Future stud-
ies should investigate whether tenderness to digital palpation
represents intra-articular pain or periarticular pain or both.
The synovial ﬂuid TNF-α levels decreased consistently
after treatment in the patients with detectable pretreatment
levels. The clinical eﬀect of glucocorticoid on TMJ pain may
thusbeexplainedbyitswell-documentedinhibitingeﬀecton
TNF-α production [1]. Besides its direct eﬀects, TNF-α also
induces production of, for example, IL-1β,I L - 6 ,I L - 8 ,a n d
prostaglandins in the inﬂamed synovial tissues [8, 9, 21, 22].
In addition, activated glucocorticoid receptors increase the
expression of genes encoding anti-inﬂammatory proteins
[1]. The observed treatment eﬀect on TMJ resting pain and
tenderness to digital palpation may thus be accomplished by
reduction of several local pain mediators or increased lo-
cal expression of anti-inﬂammatory proteins modulated by
TNF-α.
In this study, 33% of the patients had detectable levels
of TNF-α in the synovial ﬂuid at each sampling occasion,
which is in agreement with other studies of similar patient
categories [5, 23]. However, in six of the patients, the syn-
ovial ﬂuid level of TNF-α increased from undetectable to de-
tectable levels during the study period after treatment. The
small but signiﬁcant increase in C-reactive protein observed
in the whole patient sample indicates a slight increase in the
systemicinﬂammatoryactivityoverthefollowupperiod.The
observed increase in synovial ﬂuid TNF-α levels is proba-
bly related to this increased systemic inﬂammatory activity.
This is supported by the tendency to an association between
the increase of synovial ﬂuid TNF-α and C-reactive protein.
The local release of TNF-α in the TMJ is thus most likely in-
creased by increased systemic inﬂammation and higher con-
comitant C-reactive protein level. Another but less likely ex-
planation is that the length of the time period between treat-
ment and followup was too long for a reasonable possibility
to detect a temporary reduction in synovial ﬂuid TNF-α af-
ter treatment. However, no diﬀerence could be observed be-
tween patients with shorter intervals compared to longer in-
tervals regarding the treatment eﬀect on synovial ﬂuid TNF-
α. In addition, those patients with a detectable pretreatment
level of synvial ﬂuid TNF-α, who possibly could show a re-
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In this study, all patients had mediators in the TMJ syn-
ovial ﬂuid indicating an inﬂammatory process, which sup-
ported the clinical diagnosis of “TMJ inﬂammatory disor-
der” as to whether there was a true intra-articular inﬂamma-
tory condition. The synovial ﬂuid mediator proﬁle observed
in this study was similar among the various clinical diagnos-
tic subgroups.
In conclusion, this study indicates that presence of TNF-
α in the synovial ﬂuid predicts a treatment eﬀect of intra-
articular injection of glucocorticoid on TMJ movement pain
in patients with chronic TMJ inﬂammatory disorders.
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